1. Home
  2. XENE vs ICUI Comparison

XENE vs ICUI Comparison

Compare XENE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XENE

Xenon Pharmaceuticals Inc.

HOLD

Current Price

$42.43

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

BUY

Current Price

$150.10

Market Cap

3.6B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
XENE
ICUI
Founded
1996
1984
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.6B
IPO Year
2014
1992

Fundamental Metrics

Financial Performance
Metric
XENE
ICUI
Price
$42.43
$150.10
Analyst Decision
Strong Buy
Buy
Analyst Count
11
5
Target Price
$53.91
$179.50
AVG Volume (30 Days)
857.1K
211.6K
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,500,000.00
$2,320,363,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.74
$107.00
52 Week High
$46.60
$175.51

Technical Indicators

Market Signals
Indicator
XENE
ICUI
Relative Strength Index (RSI) 44.90 60.16
Support Level $40.41 $137.43
Resistance Level $46.36 $149.00
Average True Range (ATR) 1.59 4.29
MACD -0.43 -0.26
Stochastic Oscillator 30.35 84.73

Price Performance

Historical Comparison
XENE
ICUI

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: